- Home
- TECH vs CWAN Comparison
TECH vs CWAN Comparison
Compare TECH & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECH
- CWAN
- Stock Information
- Founded
- TECH 1976
- CWAN 2004
- Country
- TECH United States
- CWAN United States
- Employees
- TECH N/A
- CWAN N/A
- Industry
- TECH Biotechnology: Biological Products (No Diagnostic Substances)
- CWAN Computer Software: Prepackaged Software
- Sector
- TECH Health Care
- CWAN Technology
- Exchange
- TECH Nasdaq
- CWAN Nasdaq
- Market Cap
- TECH 7.8B
- CWAN 6.1B
- IPO Year
- TECH 1989
- CWAN 2021
- Fundamental
- Price
- TECH $53.94
- CWAN $21.77
- Analyst Decision
- TECH Buy
- CWAN Buy
- Analyst Count
- TECH 12
- CWAN 10
- Target Price
- TECH $70.00
- CWAN $31.50
- AVG Volume (30 Days)
- TECH 1.9M
- CWAN 4.1M
- Earning Date
- TECH 08-06-2025
- CWAN 07-30-2025
- Dividend Yield
- TECH 0.59%
- CWAN N/A
- EPS Growth
- TECH N/A
- CWAN N/A
- EPS
- TECH 0.83
- CWAN 1.71
- Revenue
- TECH $1,208,770,000.00
- CWAN $475,948,000.00
- Revenue This Year
- TECH $7.07
- CWAN $63.43
- Revenue Next Year
- TECH $5.72
- CWAN $29.94
- P/E Ratio
- TECH $65.29
- CWAN $12.75
- Revenue Growth
- TECH 4.72
- CWAN 23.21
- 52 Week Low
- TECH $46.01
- CWAN $17.94
- 52 Week High
- TECH $83.62
- CWAN $35.71
- Technical
- Relative Strength Index (RSI)
- TECH 59.94
- CWAN 44.69
- Support Level
- TECH $50.97
- CWAN $21.39
- Resistance Level
- TECH $55.53
- CWAN $22.92
- Average True Range (ATR)
- TECH 2.07
- CWAN 0.65
- MACD
- TECH 0.24
- CWAN 0.06
- Stochastic Oscillator
- TECH 77.60
- CWAN 45.33
About TECH Bio-Techne Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.